ENTRESTO MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global ENTRESTO Market Size and Forecast – 2025 - 2032

The Global ENTRESTO Market is estimated to be valued at USD 9.09 Bn in 2025 and is expected to reach USD 12.21 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032. This steady growth reflects the increasing prevalence of cardiovascular diseases and the rising adoption of advanced therapies for heart failure management worldwide. Market expansion is further supported by ongoing research, improved healthcare infrastructure, and growing awareness among patients and healthcare providers.

Key Takeaways of the global ENTRESTO market

• Chronic Heart Failure (CHF) is the primary driver of growth in the global ENTRESTO market, accounting for an estimated 75.2% of the market share in 2025.
• In terms of dosage forms, film-coated tablets dominate, holding an estimated 68.4% market share in 2025.
• Among the various strengths, the 24/26 mg formulation is expected to lead with a 23.2% market share in 2025, highlighting its importance as the standard starting dose for most patients beginning treatment.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.5% in 2025.

Market Overview

Current market trends highlight a strong shift towards personalized medicine and advancements in drug formulations to enhance patient compliance and efficacy. Additionally, increasing investment in R&D for combination therapies and expanding patient populations are driving revenue growth. The trend toward digital health integration, including remote monitoring and telemedicine solutions, is also influencing ENTRESTO’s market penetration, enabling better disease management and improving treatment outcomes across diverse geographies.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

ENTRESTO Market Insights, By Indication - Leading Demand from Chronic Heart Failure (CHF) Fuels Market Dominance

In terms of indication, Chronic Heart Failure (CHF) stands out as the primary driver of growth within the global ENTRESTO market with an estimated share of 75.2% in 2025. This prominence largely stems from the increasing prevalence and clinical importance of CHF as a chronic, progressive cardiovascular condition marked by the heart's inability to pump blood effectively. ENTRESTO, a combination of sacubitril and valsartan, has gained strong acceptance as a frontline therapy for CHF, owing to its proven efficacy in reducing mortality and hospitalizations compared to conventional treatments. The broad adoption of ENTRESTO for managing CHF is supported by clinical guidelines endorsing its use in patients with reduced ejection fraction, positioning it as integral in standard care protocols. Another critical factor propelling the CHF segment is the growing awareness among healthcare providers and patients regarding the long-term benefits of optimized heart failure management.

In September 2024, according to the Heart Failure Society of America's (HFSA) Epidemiology Forecast Report to 2028, the number of diagnosed prevalent cases of chronic heart failure (CHF) in the eight major markets (8MM) is expected to increase from 26.8 million in 2018 to 32.2 million by 2028, growing at an annual rate of 2.02%. Approximately 40% of these cases are in the elderly population, and this proportion is projected to rise by 40% over the next decade. This growth is driven by longer life expectancy, better early diagnosis through advanced screening, and the use of effective treatments for managing heart failure with multiple comorbidities.

ENTRESTO Market Insights, By Dosage Forms - Film-Coated Tablets Command Market Share, due to Patient Compliance and Stability

When examining ENTRESTO through the lens of dosage forms, film-coated tablets represent the most significant segment with an estimated share of 68.4% in 2025, primarily driven by practical considerations related to patient adherence, ease of administration, and stability of the drug compound. Film-coated tablets are widely favored in clinical settings due to their convenience, allowing once or twice daily dosing that fits seamlessly into patients’ daily routines. This ease of use is particularly important for chronic conditions such as heart failure, where long-term, uninterrupted treatment adherence is critical to achieving optimal therapeutic outcomes.

The film coating itself offers additional benefits by protecting the active ingredients from degradation caused by moisture or gastric acids, thereby enhancing the overall shelf-life and bioavailability of the medication. This ensures consistent efficacy, which is paramount for patients reliant on stable, predictable drug performance to manage their heart condition effectively. Furthermore, the coating can mask any unpleasant taste or odor, improving patient acceptance, especially among the elderly or those with swallowing difficulties.

ENTRESTO Market Insights, by strength - Dominance of 24/26 mg Strength Driven by Treatment Initiation and Titration ENTRESTO Market Insights, Practices

In the segment divided by strength, the 24/26 mg formulation of ENTRESTO leads market share with an estimated 23.2% in 2025, reflecting its critical role as the starting dose for most patients initiating therapy. This lower strength dose is essential in clinical practice for several reasons, foremost among them being the safety and tolerability considerations during the early phases of treatment. Physicians commonly begin with the 24/26 mg strength to minimize risks of hypotension or renal dysfunction, especially in patients who may have concurrent clinical complexities or are naïve to angiotensin receptor-neprilysin inhibitor therapy.

The availability and preference for this strength facilitate gradual dose escalation, allowing healthcare providers to carefully titrate patients to higher doses, such as 49/51 mg or 97/103 mg, based on individual response and tolerability. This stepwise approach optimizes therapeutic efficacy while reducing adverse effects, which is critical for improving patient adherence and long-term treatment success. Therefore, the 24/26 mg strength functions as a pivotal entry point in the clinical management pathway, driving its high utilization.

ENTRESTO Reimbursement Policy

• ENTRESTO offers a USD 10 co-pay card for eligible commercially insured patients, allowing them to pay as little as USD 10 for a 30-, 60-, or 90-day supply of the medication. This offer is available at retail and mail-order pharmacies, with a combined annual limit of USD 4,100 across all fills. Once the annual limit is reached, patients are responsible for any additional costs. The program is not valid under Medicare, Medicaid, or any other federal or state programs, and eligibility is limited to specific commercial insurance plans.
• Additionally, if a mail-order pharmacy cannot process the co-pay offer, patients can request a rebate by submitting a completed form along with their pharmacy receipt. For more information on eligibility and program details, patients should check with their insurance provider or visit the program’s website.

Regional Insights

To learn more about this report, Download Free Sample

North America ENTRESTO Market Analysis and Trends

In North America, the dominance in the global ENTRESTO market is driven primarily by a robust healthcare infrastructure with an estimated share of 38.3% in 2025, widespread physician awareness, and early adoption of advanced heart failure therapies. The presence of strong regulatory frameworks by bodies such as the FDA facilitates quicker approvals and encourages innovation. Additionally, high healthcare expenditure and extensive insurance coverage enable broader patient access to premium therapies like ENTRESTO. The market ecosystem is supported by leading pharmaceutical companies such as Novartis, which heavily promote ENTRESTO through extensive clinical research collaborations and marketing campaigns in the US and Canada. Moreover, North America's well-developed supply chain and distribution networks & government plans to help ensure steady availability, bolstering market penetration.

In February 2025, the American Heart Association (AHA) launched a new initiative, aimed at addressing knowledge gaps among clinicians and improving access to advanced heart failure (HF) therapies. With the prevalence of HF projected to reach 11.4 million by 2050, the initiative will focus on educating specialists and clinical teams about treatment pathways beyond traditional therapies. The goal is to enhance patient outcomes by providing information on care models for heart failure management and reducing disparities in advanced HF treatment.

Asia Pacific ENTRESTO Market Analysis and Trends

Meanwhile, the Asia Pacific region is projected to exhibit the fastest growth in the ENTRESTO market with share of 25.5% in 2025, fueled by increasing cardiovascular disease prevalence, expanding healthcare infrastructure, and rising patient awareness. Rapid urbanization and changing lifestyles contribute significantly to the growth of heart failure cases, creating increasing demand for effective treatments. Government initiatives aimed at improving healthcare access, such as reimbursement policies and health insurance schemes in countries like China and India, also facilitate market expansion.

In September 2023, the World Health Organization (WHO) launched the South-East Asia-HEARTS (SEAHEARTS) initiative across the WHO South-East Asia Region, aiming to reduce the burden of cardiovascular diseases, which are a leading cause of death. The program focuses on scaling up treatment and control of hypertension and diabetes, and integrating non-communicable disease (NCD) risk reduction on a single platform. Cardiovascular diseases account for 3.9 million deaths annually in the region, with preventable risk factors like tobacco use, unhealthy diets, and high blood pressure contributing significantly.

ENTRESTO Market Outlook for Key Countries

U.S. ENTRESTO Market Trends

The U.S. represents the largest market within North America due to its advanced healthcare infrastructure and high patient adoption of innovative cardiovascular drugs. Novartis, the primary developer of ENTRESTO, leverages strong relationships with healthcare providers and key opinion leaders to maintain market leadership. Government regulations allow for streamlined approvals and post-marketing surveillance, ensuring safety and efficacy, which builds physician confidence. The presence of major health insurance programs further guarantees patient access, supporting steady market growth.

In North America, key health insurance programs include Medicare (for seniors and certain disabled individuals), Medicaid (for low-income individuals), and private insurance (employer-based or individual plans). These programs play a crucial role in providing healthcare access, managing acute care utilization, and addressing affordability for adults with cardiovascular disease (CVD).

Germany ENTRESTO Market Trends

Germany’s ENTRESTO market benefits from the country’s well-established healthcare system and supportive reimbursement policies for cardiovascular therapies. The presence of a strong pharmaceutical manufacturing base and active participation of companies like Novartis and local distributors enhances market penetration. The government’s focus on preventive healthcare and chronic disease management leads to increased physician endorsement of guideline-recommended treatments like ENTRESTO. Germany also serves as a gateway to other European markets due to its strategic location and robust trade logistics.

China ENTRESTO Market Trends

The market in China is rapidly expanding due to increased cardiovascular disease incidence and enhanced governmental support to improve chronic disease outcomes. Recent reforms promoting affordable access to innovative medications, combined with domestic investments in healthcare infrastructure, create a favorable environment. China has launched several initiatives to combat cardiovascular diseases (CVD), including the Healthy China 2030 plan, which aims to improve health and control major risk factors like CVDs. Additionally, the China PEACE Million Persons Project focuses on screening and managing high-risk individuals to reduce CVD mortality.

These efforts reflect China’s commitment to improving cardiovascular health through prevention, early detection, and better access to care. The growing adoption of health insurance and government-led reimbursement schemes further enable patient affordability, accelerating market uptake.

India ENTRESTO Market Trends

India’s ENTRESTO market growth is propelled by rising awareness of heart failure and improving healthcare access through government insurance schemes. Despite cost sensitivity, increasing physician acceptance and ongoing clinical education help to drive the adoption of this breakthrough therapy. In September 2023, On World Heart Day, the Government of India launched a public campaign focused on heart health, emphasizing the importance of controlling hypertension, a leading risk factor for cardiovascular diseases.

The campaign encourages healthy lifestyle changes, including adopting an active lifestyle, eating nutritious foods, and reducing tobacco and alcohol consumption. Novartis, along with other regional pharmaceutical players, is improving distribution channels and engaging in patient assistance programs to expand access in both urban and rural areas. The expanding healthcare infrastructure and digitization in healthcare delivery also enhance treatment awareness.

End User Feedback and Unmet Needs in the Global ENTRESTO Market

• End user feedback on ENTRESTO in the global heart failure treatment market reflects both satisfaction and concerns across key application sectors. A positive example comes from healthcare providers who have reported significant improvement in patient outcomes when ENTRESTO is used in combination with other heart failure therapies. For instance, cardiologists in the U.S. have praised ENTRESTO for its ability to reduce hospitalizations and improve left-ventricular ejection fraction (LVEF), particularly in patients with reduced ejection fraction heart failure. The combination therapy has been lauded for its effectiveness in managing comorbid conditions such as hypertension and diabetes, offering a multi-faceted approach to heart failure management. However, some healthcare professionals have voiced concerns about the complexity of treatment regimens and the difficulty in ensuring patient adherence to the dual-drug combination, especially in the elderly population with multiple comorbidities. Additionally, concerns regarding the high cost of ENTRESTO, particularly in developing markets, have been frequently cited, limiting its accessibility to a broader patient demographic.
• The unmet needs in the ENTRESTO market revolve primarily around the affordability of the treatment, especially in regions with limited healthcare budgets. Although ENTRESTO has proven to be highly effective, its cost remains a barrier for widespread adoption, especially in low- and middle-income countries. Furthermore, there is a need for more personalized treatment options that account for genetic and environmental factors, which could increase the effectiveness and reduce the side effects for certain patient groups. The lack of sufficient patient education materials and support programs also hampers the treatment's potential impact. Addressing these gaps by offering more affordable solutions, expanding support programs, and exploring technological innovations for personalized treatment could open new growth opportunities, improve customer retention, and drive further innovation in heart failure care.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In March 2024, Otsuka Pharmaceutical Co., Ltd. announced that Novartis Pharma K.K. received approval in Japan for Entresto Granular Tablets (12.5 mg/31.25 mg) for pediatric use in treating chronic heart failure. This new formulation of sacubitril/valsartan is specifically designed for pediatric patients. Under a co-promotion agreement, Novartis Pharma and Otsuka will provide healthcare professionals with information on Entresto.
• In December 2024, Novartis AG Pharmaceuticals has suffered a legal setback in its efforts to block the launch of a generic version of Entresto (sacubitril/valsartan) by MSN Pharma. The U.S. Court of Appeals for the Federal Circuit upheld a lower court's decision to deny Novartis' request for an injunction, allowing MSN Pharma to proceed with its generic's launch. Novartis had sought to block the generic based on a patent covering the crystalline form of the active ingredients, but the court ruled that Novartis did not present sufficient evidence to justify halting the launch.
• In February 2021, Novartis AG, a global healthcare leader, has received U.S. Food and Drug Administration (U.S. FDA) approval for the expanded indication of Entresto (sacubitril/valsartan), making it the first therapy approved for both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). The approval allows Entresto to treat adult patients with chronic heart failure (CHF) and left ventricular ejection fraction (LVEF) below normal, a group that benefits most from the treatment. This expanded label provides a therapeutic option for an additional 5 million U.S. patients, of the 6 million living with CHF.

Market Report Scope

ENTRESTO Market Dynamics

To learn more about this report, Download Free Sample

ENTRESTO Market Driver - Growing Prevalence of Heart Failure Worldwide

The growing prevalence of heart failure on a global scale is a significant driver propelling the demand for ENTRESTO. As chronic cardiovascular conditions continue to increase due to aging populations, sedentary lifestyles, and the rising incidence of comorbidities such as hypertension, diabetes, and obesity, the burden of heart failure intensifies worldwide. Heart failure, characterized by the heart’s inability to pump sufficient blood to meet the body’s needs, often results in frequent hospitalizations and diminished quality of life, underscoring the urgent need for effective management options. ENTRESTO, as a combination therapy targeting the neurohormonal pathways involved in heart failure progression, offers improved clinical outcomes by reducing mortality and hospitalization rates.

In May 2025, According to European Society of Cardiology, Heart failure affects more than 60 million people globally, with its prevalence continuing to rise as the global population ages. Approximately 6.7 million Americans over 20 years of age currently have heart failure (HF), and this number is expected to rise to 8.7 million in 2030, 10.3 million in 2040, and 11.4 million by 2050. Despite significant advances in diagnosis and management, heart failure remains one of the leading causes of death, particularly in its advanced stages, where it is more lethal than many malignancies. With increasing awareness and treatment options, the global medical community is continuously working to improve outcomes for patients, making events like Heart Failure 2025 crucial for sharing the latest breakthroughs in research and patient care.

ENTRESTO Market Opportunity - Development of Combination Therapies in the Global ENTRESTO Market

The growing emphasis on personalized and precision medicine presents a significant opportunity for the development of combination therapies within the Global ENTRESTO market. ENTRESTO, primarily used for treating heart failure, has demonstrated substantial efficacy in improving cardiovascular outcomes. Collaborations between pharmaceutical companies and biotech firms to develop novel combination therapies incorporating ENTRESTO alongside other agents—such as SGLT2 inhibitors, mineralocorticoid receptor antagonists, or anti-inflammatory drugs—can enhance therapeutic efficacy and patient outcomes. Additionally, exploring fixed-dose combinations can improve patient adherence by simplifying treatment protocols, which is critical given the chronic nature of heart failure management.

aA recent study published by Biomedical Journal in June 2023, has demonstrated that combining dapagliflozin and Entresto offers superior benefits in improving heart function compared to using either treatment alone. In an experiment with rats following ischemia-reperfusion (IR) injury, the combination therapy significantly improved left-ventricular ejection fraction (LVEF) and reduced oxidative stress, fibrosis, apoptosis, and inflammation markers. The results highlight the potential of combining Entresto with other therapies to enhance treatment efficacy, particularly in heart failure management, and pave the way for future combination therapies in the global ENTRESTO market.

Analyst Opinion (Expert Opinion)

• The global ENTRESTO market is experiencing robust growth driven by a combination of technological advancements, increasing regulatory support, and the rising demand for effective heart failure treatments. The ongoing development of combination therapies, such as sacubitril/valsartan (Entresto) with dapagliflozin, is expected to further enhance the therapeutic efficacy of heart failure management, expanding the market's potential. Moreover, supportive regulatory frameworks, particularly from entities like the U.S. FDA and EMA, have accelerated market adoption. However, challenges persist, including high treatment costs and the looming threat of generic competition as patents expire. Despite these hurdles, the market presents opportunities in emerging markets where healthcare infrastructure is improving, and increasing heart failure prevalence is creating demand for novel therapies.
• Recent global events have significantly influenced the ENTRESTO market, such as the Heart Failure 2025 congress in Belgrade, Serbia, which gathered leading experts and healthcare professionals to discuss advancements in heart failure research and treatment. Additionally, real-world studies on the combination of sacubitril/valsartan and dapagliflozin have demonstrated improved patient outcomes, showcasing the growing importance of multi-drug treatments. As a result, pharmaceutical collaborations and government-backed health programs are set to shape the future of heart failure care, particularly in high-risk regions. These efforts are likely to drive continued market growth, positioning ENTRESTO as a cornerstone in the cardiovascular therapeutic landscape.

Market Segmentation

• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Chronic Heart Failure (CHF)
  • Symptomatic heart failure with left ventricular systolic dysfunction in pediatric patients
• Dosage Forms Insights (Revenue, USD Bn, 2020 - 2032)
  • Film-coated tablets
  • Film-coated oral pellets within capsules
• Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 24/26 mg
  • 49/51 mg
  • 97/103 mg
  • 6 mg/6 mg
  • 15 mg/16 mg
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adults
  • Pediatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Clinics
  • Cardiology Centers
  • Long-Term Care Facilities
  • Ambulatory Care Centers
  • Homecare Settings
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Novartis AG

Sources

Primary Research Interviews

• Industry Stakeholders
• Pharmaceutical manufacturers (including Novartis, the maker of ENTRESTO)
• Cardiologists and healthcare providers specializing in heart failure treatment
• Regulatory experts from bodies such as the FDA, EMA, and PMDA
• End users
• Hospitals and clinics offering heart failure treatments
• Healthcare providers prescribing ENTRESTO for heart failure patients
• General practitioners involved in managing cardiovascular conditions

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• Global Health Observatory (WHO)
• U.S. National Library of Medicine

Trade Publications

• Journal of the American College of Cardiology (JACC)
• Circulation: Journal of the American Heart Association
• European Heart Journal
• Cardiology Today
• The Lancet – Cardiovascular Medicine
• Heart Failure Journal

Academic Journals

• The American Journal of Cardiology
• Journal of Clinical Investigation
• British Medical Journal (BMJ)
• European Journal of Heart Failure
• Cardiovascular Research Journal
• Journal of Cardiovascular Pharmacology

Reputable Newspapers

• The New York Times
• The Guardian
• The Wall Street Journal
• Financial Times
• Reuters
• Bloomberg

Industry Associations

• American College of Cardiology (ACC)
• European Society of Cardiology (ESC)
• Heart Failure Society of America (HFSA)
• American Heart Association (AHA)
• International Society for Heart Research (ISHR)

Public Domain Resources

• National Institutes of Health (NIH) Clinical Trials Database
• U.S. National Library of Medicine (NLM)
• World Health Organization (WHO) Global Health Observatory

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years